Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Molecular Pharmaceutics|December 30, 2015
Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5Amanda Shanks Huynh, Veronica Estrella, Valerie E Stark, et al.
Environmental Science & Technology|March 18, 2023
Improved Decision Making for Water Lead Testing in U.S. Child Care Facilities Using Machine-Learned Bayesian NetworksRiley E Mulhern, A J Kondash, Ed Norman, et al.
Cancer Cell International|December 20, 2017
The human, F-actin-based cytoskeleton as a mutagen sensorNicolette M Clark, Carlos A Garcia Galindo, Vandan K Patel, et al.
Pediatrics|May 18, 2019
Ambulatory Management of Childhood Asthma Using a Novel Self-management ApplicationFlory L Nkoy, Bernhard A Fassl, Victoria L Wilkins, et al.
Surgery|October 1, 2013
Anastomotic leak or organ space surgical site infection: What are we missing in our quality improvement programs?Aaron S Rickles, James C Iannuzzi, Kristin N Kelly, et al.
Blood Advances|April 23, 2021
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromesGrace A Ward, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 2, 2024
Pathogenic Roles for RNASET2 in Clear Cell Renal Cell CarcinomaTaylor Peak, Yijun Tian, Aman Patel, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2013
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patientsGisela Caceres, Kathy McGraw, Bon Ham Yip, et al.
Blood|October 15, 2016
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotypeAshley A Basiorka, Kathy L McGraw, Erika A Eksioglu, et al.
Pageof 8